For more information about Sofwave or other non-invasive treatment options, call 914-730-3333
Restrictive eating disorders A joint advisory from obesity and nutrition societies notes that restrictive eating disorders are a general contraindication to GLP-1 use
Whey protein in particular has been shown to stimulate a stronger GLP-1 response than casein or soy
reports research support for clinical trials leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA and CSL Behring, as well as honoraria for consultancy from Lilly USA, Pfizer, Boehringer Ingelheim, Lexicon, Novo Nordisk, Applied Therapeutics, Altimmune, CSL Behring, Bayer, Intercept and New Amsterdam